AR037141A1 - Un metodo para identificar interacciones entre dos farmacos y una disposicion de screening de bibliotecas para determinar la interaccion de un farmaco de ensayo con un miembro de una biblioteca de farmacos en un ensayo - Google Patents

Un metodo para identificar interacciones entre dos farmacos y una disposicion de screening de bibliotecas para determinar la interaccion de un farmaco de ensayo con un miembro de una biblioteca de farmacos en un ensayo

Info

Publication number
AR037141A1
AR037141A1 ARP020103231A ARP020103231A AR037141A1 AR 037141 A1 AR037141 A1 AR 037141A1 AR P020103231 A ARP020103231 A AR P020103231A AR P020103231 A ARP020103231 A AR P020103231A AR 037141 A1 AR037141 A1 AR 037141A1
Authority
AR
Argentina
Prior art keywords
library
drugs
drug
trial
interaction
Prior art date
Application number
ARP020103231A
Other languages
English (en)
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of AR037141A1 publication Critical patent/AR037141A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Abstract

Un método para identificar una interacción entre dos fármacos, método que comprende los siguientes pasos: (a) procurar (i) un fármaco de ensayo; (ii) una biblioteca de fármacos que tenga por lo menos 200 fármacos diferentes y (iii) un ensayo, donde por lo menos 200 de dichos fármacos de la biblioteca son fármacos aprobados por una agencia reguladora gubernamental para la administración a un paciente; (b) poner en contacto a dicho fármaco de ensayo y por lo menos 200 fármacos de dicha biblioteca de fármacos de dicho ensayo en condiciones que garanticen que el contacto de cada fármaco de ensayo/fármaco de biblioteca sea segregado de los otros; (c) registrar el resultado de dicho paso de contacto (b) y; (d) identificar las combinaciones de fármacos que produzcan en dicho ensayo un resultado diferente de los resultados producidos por cualquiera de los fármacos de la combinación por sí solo, donde cada una de las combinaciones identificadas indica una interacción entre el fármaco de ensayo y el fármaco de la biblioteca de dicha combinación. De acuerdo con el método, cada una de las combinaciones identificadas indica una interacción entre el fármaco de ensayo y el fármaco de la biblioteca. También se describen una disposición de screening de bibliotecas para determinar la interacción de un fármaco de ensayo con un miembro de una biblioteca de fármacos en un ensayo.
ARP020103231A 2001-08-29 2002-08-28 Un metodo para identificar interacciones entre dos farmacos y una disposicion de screening de bibliotecas para determinar la interaccion de un farmaco de ensayo con un miembro de una biblioteca de farmacos en un ensayo AR037141A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31588401P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
AR037141A1 true AR037141A1 (es) 2004-10-27

Family

ID=23226480

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103231A AR037141A1 (es) 2001-08-29 2002-08-28 Un metodo para identificar interacciones entre dos farmacos y una disposicion de screening de bibliotecas para determinar la interaccion de un farmaco de ensayo con un miembro de una biblioteca de farmacos en un ensayo

Country Status (8)

Country Link
US (2) US20030096309A1 (es)
EP (1) EP1432986A4 (es)
JP (1) JP2005502049A (es)
AR (1) AR037141A1 (es)
AU (1) AU2002323317B2 (es)
CA (1) CA2459055A1 (es)
TW (1) TW573125B (es)
WO (1) WO2003021264A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004088272A2 (en) * 2003-03-26 2004-10-14 Synergy Biosystems Ltd. Methods to identify biologically active agents and synergistic combinations
CA2528508A1 (en) * 2003-06-06 2004-12-16 Combinatorx Incorporated System and method for multidimensional evaluation of combinations of compositions
EP1512970A1 (en) * 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for determining the impact of a multicomponent mixture on the biological profile of a disease
US20080241129A1 (en) * 2007-02-16 2008-10-02 Wyeth Adipocyte secreted protein ccdc80 is a potent stimulator of bone formation
JP2012504770A (ja) * 2008-10-06 2012-02-23 シムフォゲン・アクティーゼルスカブ コンビナトリアルドラッグについての薬物の候補物質を同定および選択する方法
AU2012230880B2 (en) 2011-03-24 2017-04-13 Opko Pharmaceuticals, Llc Biomarker discovery in complex biological fluid using bead or particle based libraries and diagnostic kits and therapeutics
WO2013123403A1 (en) * 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
US9085793B2 (en) 2012-06-11 2015-07-21 XPD Consulting, LLC Ex vivo methods to identify circulating drug metabolites with drug interaction potential
US10223500B2 (en) 2015-12-21 2019-03-05 International Business Machines Corporation Predicting drug-drug interactions and specific adverse events
TWI622012B (zh) * 2016-11-18 2018-04-21 財團法人資訊工業策進會 藥物組合預測系統及藥物組合預測方法
JP2018091790A (ja) * 2016-12-06 2018-06-14 東ソー株式会社 細胞の染色方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
CA2058252A1 (en) * 1991-03-18 1992-09-19 Linda R. Robertson Synergistic product selection test for biocides
US5833599A (en) * 1993-12-13 1998-11-10 Multum Information Services Providing patient-specific drug information
US5985356A (en) * 1994-10-18 1999-11-16 The Regents Of The University Of California Combinatorial synthesis of novel materials
US5756304A (en) * 1995-07-14 1998-05-26 Molecular Solutions Screening of microorganisms for bioremediation
US5989835A (en) * 1997-02-27 1999-11-23 Cellomics, Inc. System for cell-based screening
US6030942A (en) * 1996-08-30 2000-02-29 The Trustees Of The University Of Pennsylvania Peptides peptide analogs peptidomimetics and other small molecules useful for inhibiting the activity of ribonucleotide reductase
US5965352A (en) * 1998-05-08 1999-10-12 Rosetta Inpharmatics, Inc. Methods for identifying pathways of drug action
US5992226A (en) * 1998-05-08 1999-11-30 The United States Of America As Represented By The Secretary Of The Navy Apparatus and method for measuring intermolecular interactions by atomic force microscopy
AU4077499A (en) * 1998-05-15 1999-12-06 Glaxo Group Limited Infrared thermography
US6219674B1 (en) * 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US20030036683A1 (en) * 2000-05-01 2003-02-20 Kehr Bruce A. Method, system and computer program product for internet-enabled, patient monitoring system
US20020019011A1 (en) * 2000-07-07 2002-02-14 Stockwell Brent R. Methods for identifying combinations of entities as therapeutics
JP2004522935A (ja) * 2000-08-14 2004-07-29 サーフェイス ロジックス，インコーポレイティド 生体分子アレイ

Also Published As

Publication number Publication date
AU2002323317B2 (en) 2006-08-10
WO2003021264A1 (en) 2003-03-13
US20030096309A1 (en) 2003-05-22
TW573125B (en) 2004-01-21
CA2459055A1 (en) 2003-03-13
EP1432986A4 (en) 2007-02-21
JP2005502049A (ja) 2005-01-20
US20080194421A1 (en) 2008-08-14
EP1432986A1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
Ferrarese et al. Increased glutamate in CSF and plasma of patients with HIV dementia
Kowalski et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management
Knierim Dynamic interactions between local surface cues, distal landmarks, and intrinsic circuitry in hippocampal place cells
Waters et al. The reliability and stability of verbal working memory measures
AR037141A1 (es) Un metodo para identificar interacciones entre dos farmacos y una disposicion de screening de bibliotecas para determinar la interaccion de un farmaco de ensayo con un miembro de una biblioteca de farmacos en un ensayo
Pittler et al. Location bias in controlled clinical trials of complementary/alternative therapies
Bagnall et al. Multiple clusters of release sites formed by individual thalamic afferents onto cortical interneurons ensure reliable transmission
Dalezios et al. Enrichment of mGluR7a in the presynaptic active zones of GABAergic and non-GABAergic terminals on interneurons in the rat somatosensory cortex
GB2420204A (en) System, method, and apparatus for evaluating a person's athletic ability
BR9909906A (pt) Sistemas, métodos e produtos de programa de computador para guiar a seleção de regimes de tratamento terapêutico
BR0016903A (pt) Método de distribuição de drogas evitando ocorrência de efeitos colaterais adversos conhecidos ou suspeitos
AR029583A1 (es) Diagnostico precoz de enfermedades de conformacion
ATE278803T1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
Cobb et al. Activation of nicotinic acetylcholine receptors patterns network activity in the rodent hippocampus
BR0315184A (pt) Método e aparelho para auto-acompanhamento de estados corporais contìnuos ou discretos utilizando parâmetros fisiológicos e/ou contextuais
BR0214929A (pt) métodos e composições para o tratamento de distúrbios do sistema nervoso central
Gholizadeh et al. Early versus late-phase consolidation of opiate reward memories requires distinct molecular and temporal mechanisms in the amygdala-prefrontal cortical pathway
Meyer et al. Rewarding effects of the optical isomers of 3, 4-methylenedioxy-methylamphetamine (‘Ecstasy’) and 3, 4-methylenedioxy-ethylamphetamine (‘Eve’) measured by conditioned place preference in rats
Unno et al. Receptor signaling mechanisms underlying muscarinic agonist‐evoked contraction in guinea‐pig ileal longitudinal smooth muscle
SG148027A1 (en) Methods for identifying combinations of entities as therapeutics
Faust et al. Relationship between moral and Piagetian reasoning and the effectiveness of moral education.
Fernaeus et al. Late reaction times identify MCI
Kohda et al. Carbachol‐induced oscillations in membrane potential and [Ca2+] i in guinea‐pig ileal smooth muscle cells
Santos et al. Transmission efficacy and plasticity in glutamatergic synapses formed by excitatory interneurons of the substantia gelatinosa in the rat spinal cord
Hanna The application of thought to textual criticism in all modes—with apologies to AE Housman

Legal Events

Date Code Title Description
FB Suspension of granting procedure